aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [e-mail], by telephone at [phone] or visit our website at www.howardsmithlaw.com.

What Happened?

On September 15, 2025, aTyr announced that the Phase 3 study of its intravenous Efzofitimod pulmonary sarcoidosis treatment, EFZO-FIT, did not meet its primary endpoint in change from baseline in mean daily OSC dose at week 48.

On this news, aTyr’s stock price fell $5.01, or 83.2%, to close at $1.02 per share on September 15, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased aTyr securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: [phone]
Email: [e-mail],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.